Published in J Clin Invest on September 01, 2000
Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer (2008) 6.10
Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J (2002) 2.39
GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell (2008) 1.91
Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol Cell Biol (2003) 1.71
Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol Cell Biol (2001) 1.57
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer (2002) 1.43
Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer Metastasis Rev (2008) 1.32
The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer. J Cancer Res Clin Oncol (2004) 1.19
Overexpression of CDC25B and LAMC2 mRNA and protein in esophageal squamous cell carcinomas and premalignant lesions in subjects from a high-risk population in China. Cancer Epidemiol Biomarkers Prev (2008) 1.11
Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner. Mol Cell Biol (2005) 1.07
The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signal-regulating kinase 1. Mol Cell Biol (2001) 1.06
Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest. J Virol (2002) 1.05
A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers. Genome Res (2002) 1.01
The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med Chem (2012) 0.99
Cdc25A regulates matrix metalloprotease 1 through Foxo1 and mediates metastasis of breast cancer cells. Mol Cell Biol (2011) 0.96
Liver × receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism. Breast Cancer Res (2013) 0.95
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes. BMC Cancer (2010) 0.94
Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med (2010) 0.93
Mice with the CHEK2*1100delC SNP are predisposed to cancer with a strong gender bias. Proc Natl Acad Sci U S A (2009) 0.87
Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo. Mol Cancer (2008) 0.86
Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis. Neoplasia (2011) 0.86
MicroRNA-215 Regulates Fibroblast Function: Insights from a Human Fibrotic Disease. Cell Cycle (2015) 0.85
Expression of cyclin-dependent kinases and CDC25a phosphatase is related with recurrences and survival in women with peri- and post-menopausal breast cancer. Virchows Arch (2006) 0.83
CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment. Neoplasia (2013) 0.83
LGH00031, a novel ortho-quinonoid inhibitor of cell division cycle 25B, inhibits human cancer cells via ROS generation. Acta Pharmacol Sin (2009) 0.82
Phosphatases and kinases regulating CDC25 activity in the cell cycle: clinical implications of CDC25 overexpression and potential treatment strategies. Mol Cell Biochem (2016) 0.80
Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem (2008) 0.79
Microarray and pathway analysis reveals decreased CDC25A and increased CDC42 associated with slow growth of BCL2 overexpressing immortalized breast cell line. Cell Cycle (2008) 0.79
A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation. Cancer Prev Res (Phila) (2010) 0.77
Screening the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2 kinase. J Zhejiang Univ Sci B (2005) 0.77
SMG-1 suppresses CDK2 and tumor growth by regulating both the p53 and Cdc25A signaling pathways. Cell Cycle (2013) 0.76
miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev (2017) 0.75
CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 9.79
G1 events and regulation of cell proliferation. Science (1989) 9.73
Rapid destruction of human Cdc25A in response to DNA damage. Science (2000) 4.74
Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J (1992) 4.21
Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell (1991) 3.34
Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J (1994) 2.95
CDC25 phosphatases as potential human oncogenes. Science (1995) 2.84
Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. Proc Natl Acad Sci U S A (1990) 2.71
Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J (1994) 2.61
The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg (1996) 2.20
Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc Natl Acad Sci U S A (1993) 2.12
Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol Cell Biol (1999) 2.01
The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res (1997) 2.00
The cdc25B phosphatase is essential for the G2/M phase transition in human cells. J Cell Sci (1998) 1.92
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol (1993) 1.83
Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Rep (2000) 1.72
Cyclin dependent kinase regulation. Curr Opin Cell Biol (1995) 1.70
Cdc25 protein phosphatases in cell proliferation. Biochim Biophys Acta (1997) 1.47
p21CIP1 and Cdc25A: competition between an inhibitor and an activator of cyclin-dependent kinases. Mol Cell Biol (1997) 1.46
Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest (1997) 1.32
Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B. Oncogene (1999) 1.14
Cdc25 regulates the phosphorylation and activity of the Xenopus cdk2 protein kinase complex. J Biol Chem (1992) 1.12
Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer (1997) 1.09
S-phase fraction and breast cancer--a decade of experience. Breast Cancer Res Treat (1998) 1.08
Cell cycle and cancer: critical events at the G1 restriction point. Crit Rev Oncog (1996) 0.97
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34
Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A (2001) 19.30
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol (1999) 9.92
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res (1997) 8.88
Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev (1993) 8.03
Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol (1995) 6.41
Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med (1997) 5.10
Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature (2000) 4.52
Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev (1999) 4.07
Short-term effects of carbon monoxide exposure on the exercise performance of subjects with coronary artery disease. N Engl J Med (1989) 4.02
The F-box protein family. Genome Biol (2000) 4.00
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol (2001) 3.87
Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature (2000) 3.81
Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med (1997) 3.71
Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol (2000) 3.65
The DCC protein and prognosis in colorectal cancer. N Engl J Med (1996) 3.51
Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics (2000) 3.48
Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol (2000) 3.42
The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene (1999) 3.36
Identification of a family of human F-box proteins. Curr Biol (1999) 3.31
Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res (1999) 3.29
p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol (2000) 3.20
Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst (2000) 2.87
CDC25 phosphatases as potential human oncogenes. Science (1995) 2.84
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 2.61
Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A (2001) 2.55
Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: a follow-up study in an Italian population. Oral Oncol (2004) 2.46
p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J (2001) 2.45
Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci U S A (1993) 2.31
A likelihood-based method for real-time estimation of the serial interval and reproductive number of an epidemic. Stat Med (2008) 2.29
Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in G1 progression. Oncogene (1994) 2.18
Activation of protein kinase C triggers its ubiquitination and degradation. Mol Cell Biol (1998) 2.15
Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis (2000) 2.15
Use of primary breast carcinoma characteristics to predict lymph node metastases. Cancer (1997) 2.13
Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene (1994) 2.10
Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol (1998) 2.07
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res (1997) 2.05
Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest. J Biol Chem (1997) 2.05
Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. Mol Cell (2000) 2.02
CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol (2003) 2.01
The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res (1997) 2.00
Hunger in children in the United States: potential behavioral and emotional correlates. Pediatrics (1998) 1.99
Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol (2001) 1.95
Thymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nat Med (1996) 1.94
White matter disorders of prematurity: association with intraventricular hemorrhage and ventriculomegaly. The Developmental Epidemiology Network. J Pediatr (1999) 1.93
Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J (1995) 1.92
Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res (1998) 1.92
Major hepatic resection for metachronous metastases from colon cancer. Ann Surg (1985) 1.89
Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res (1994) 1.88
BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer (2008) 1.83
Gastric cancer. Contemporary aspects. Am J Surg (1977) 1.72
Changing aspects of gastric adenocarcinoma. N Engl J Med (1984) 1.72
Rescue of defective mitogenic signaling by D-type cyclins. Proc Natl Acad Sci U S A (1995) 1.71
Role of the F-box protein Skp2 in adhesion-dependent cell cycle progression. J Cell Biol (2001) 1.69
Corrected group prognostic curves and summary statistics. J Chronic Dis (1982) 1.67
Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia (1997) 1.64
Oral acanthosis nigricans, tripe palms and sign of leser-trélat in a patient with gastric adenocarcinoma. Int J Dermatol (2004) 1.62
Changing clinical, pathologic, therapeutic, and survival patterns in differentiated thyroid carcinoma. Ann Surg (1976) 1.61
Maternal infection, fetal inflammatory response, and brain damage in very low birth weight infants. Developmental Epidemiology Network Investigators. Pediatr Res (1999) 1.58
Hypocarbia during the first 24 postnatal hours and white matter echolucencies in newborns < or = 28 weeks gestation. Pediatr Res (2001) 1.58
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer (2013) 1.57
Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol (1997) 1.53
A nonparametric scoring algorithm for identifying informative genes from microarray data. Pac Symp Biocomput (2001) 1.51
Lymph node metastases. Indicators, but not governors of survival. Arch Surg (1984) 1.51
Maternal glucocorticoid therapy and reduced risk of bronchopulmonary dysplasia. Pediatrics (1990) 1.49
The Pediatric Symptom Checklist. Support for a role in a managed care environment. Arch Pediatr Adolesc Med (1995) 1.48
Survival of patients after colonic resection for carcinoma with simultaneous liver metastases. Surg Gynecol Obstet (1970) 1.48
Modulation of cyclin gene expression by adenovirus E1A in a cell line with E1A-dependent conditional proliferation. J Virol (1994) 1.46
Antenatal glucocorticoid treatment does not reduce chronic lung disease among surviving preterm infants. J Pediatr (2001) 1.44
Treatment of gastric cancer. Surg Clin North Am (1976) 1.44
Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer (2001) 1.44
Surgical treatment of biliary cystadenoma. A report of 15 cases. Arch Surg (1988) 1.43
Maternal toxemia and neonatal germinal matrix hemorrhage in intubated infants less than 1751 g. Obstet Gynecol (1988) 1.43
Cyclin A- and cyclin B-dependent protein kinases are regulated by different mechanisms in Xenopus egg extracts. EMBO J (1992) 1.41
BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem (2000) 1.40
Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res (2000) 1.40
Caution urged with repeat sentinel lymph node biopsies. Ann Oncol (2002) 1.39
Bivariate method for spatio-temporal syndromic surveillance. MMWR Morb Mortal Wkly Rep (2004) 1.39
Identification of the ubiquitin carrier proteins, E2s, involved in signal-induced conjugation and subsequent degradation of IkappaBalpha. J Biol Chem (1999) 1.39
Conservative surgery and radiation therapy for early breast cancer. Long-term cosmetic results. Arch Surg (1989) 1.37
Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. Oncogene (1993) 1.34
Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest (1997) 1.32
Regulation of the G1 to S transition by the ubiquitin pathway. FEBS Lett (2001) 1.30
The ubiquitin-mediated proteolytic pathway as a therapeutic area. J Mol Med (Berl) (1997) 1.29
Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP). Proc Natl Acad Sci U S A (1995) 1.29
Detection of clonal T-cell receptor gamma gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis. Am J Pathol (1999) 1.28
Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol (2006) 1.28